Novo Nordisk stated Tuesday it can slash its costs for Wegovy and Ozempic starting subsequent 12 months by as much as 50%, highlighting the rising competitors amongst pharmaceutical companies for purchasers looking for weight-loss medication.
The Danish drugmaker stated it plans to supply the medicines for $675 per 30 days beginning in January 2027, representing a 50% discount in worth for Wegovy and a 35% discount for Ozempic. Novo Nordisk may also promote Rybelsus, a tablet for adults with sort 2 diabetes that’s typically used for weight reduction, for a similar worth.
Novo Nordisk’s choice comes because it competes with Eli Lilly, which sells Mounjaro and Zepbound, injectable drugs generally used for weight-loss, and with suppliers of different so-called GLP-1 remedies coming to market.
Wegovy and Ozempic are amongst dozens of medicine bought at a reduction on Trumprx.gov, a brand new on-line platform launched by the Trump administration that offers customers direct entry to decrease costs for roughly 40 medication.
In November, Novo Nordisk additionally introduced a new pricing plan for Wegovy and Ozempic to scale back prices for some clients.
The corporate on Tuesday framed its choice as a approach to improve affordability, noting in a press launch that it needs to decrease out-of-pocket prices for purchasers with high-deductible insurance policy.
“Non-public and public payers, in addition to sufferers, need entry and have been calling for decrease listing costs,” Jamey Miller, government vp of U.S. operations for Novo Nordisk, stated in a press release.
The pharmaceutical firm stated the worth cuts is not going to influence its “direct-to-patient” costs, the discounted charges that some producers provide straight to customers.
